Topas is utilizing its highly differentiated and versatile nanoparticle technology platform to develop a broad pipeline of novel therapies to treat autoimmune and antigen-driven diseases. With our Phase 2a study, we have established clinical proof of concept for the Topas Tolerance-Inducing Platform, supporting the potential application of our platform in celiac disease and in a range of other autoimmune and immune-mediated diseases.